Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
| Company dealt in | Xeris Pharmaceuticals, Inc. |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
| Date of dealing | 22 July 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
| Long | Short | ||||
|
| Number |
| (%) | Number |
| (%) |
| (1) Relevant securities | 2,297,766 3.46 | 133,861 0.20 | ||||
| (2) Derivatives (other than options) | 124,887 0.19 |
| ||||
| (3) Options and agreements to purchase/sell |
|
| ||||
| Total | 2,422,653 3.65 | 133,861 0.20 | ||||
1. DEALINGS (Note 4)
(a) Purchases and sales
|
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
| Purchase (New Borrow)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales | 131,200
8 3 28 14 68 7 5 46 7 8 5 64 18 4 4 66 4 6 18
4 14 14 | N/A
3.5200 USD 3.5400 USD 3.5668 USD 3.6300 USD 3.5604 USD 3.5500 USD 3.5380 USD 3.5208 USD 3.5386 USD 3.5100 USD 3.5180 USD 3.5351 USD 3.5300 USD 3.5525 USD 3.5450 USD 3.5472 USD 3.5550 USD 3.5167 USD 3.5075 USD
3.5200 USD 3.5800 USD 3.6300 USD |
(b) Derivatives transactions (other than options transactions)
| Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
|
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
|
(ii) Exercising
| Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
| Date of disclosure | 23 July 2021 |
| Contact name | Alwyn Basch |
| Telephone number | 0207 742 7407 |
| If a connected EFM, name of offeree/offeror with which connected | N/A |
| If a connected EFM, state nature of connection (Note 10) | N/A |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
